Sign inJoin waitlistJoin the waitlist

AM

Arjun Mittra

Physician · Ohio State University College of Medicine

Credentials: · · · · · ·

History

Ohio State University College of Medicine
2021–Present

Hematology and Medical Oncology
Mayo Clinic College of Medicine and Science
2015–2018
Memorial Sloan Kettering Cancer Center
2012–2015
Terna Medical College, Nerul
2005–2009

Research

A review of mechanisms of resistance to immune checkpoint inhibitors and potential strategies for therapy
Review · Cancer Drug Resistance · 2020 · 72 citations
Safety and Activity of Immune Checkpoint Inhibitors in People Living With HIV and Cancer: A Real-World Report From the Cancer Therapy Using Checkpoint Inhibitors in People Living…
Journal of Clinical Oncology · 2023 · 65 citations
Safety, Antitumor Activity, and Biomarker Analysis in a Phase I Trial of the Once-daily Wee1 Inhibitor Adavosertib (AZD1775) in Patients with Advanced Solid Tumors
Clinical Cancer Research · 2021 · 64 citations

Abdul Naqash
9 papers · 1 as a fellow
Ashish Manne
9 papers · 8 as a fellow
Yuman Fong
8 papers
Anne Noonan
7 papers
PM
Pannaga Malalur
6 papers
AC
Alice Chen
5 papers
Amin Nassar
5 papers · 2 as a fellow
Joshua Carson
5 papers · 5 as a resident
JA
Joyce Au
5 papers · 5 as a resident
Mingjia Li
5 papers
NT
Naoko Takebe
5 papers
NJ
Ning Jin
5 papers

Grants

A Phase-1 Trial of Intraperitoneal 5-Fluorouracil and Oxaliplatin in Patients with Colorectal Cancer and Unresectable Peritoneal Metastasis.
National Cancer Institute · R21
Contact PI · $336.4K · Ohio State University
2023–2027

Clinical trials

Intraperitoneal Oxaliplatin and Fluorouracil for the Treatment of Patients With Peritoneal Metastases From Colorectal Cancer
Principal investigator · Active not recruiting · Phase 1
Arjun Mittra
2024–2026
Study of Nab-Paclitaxel and Gemcitabine and Plus/Minus VCN-01 in Patients With Metastatic Pancreatic Cancer
Principal investigator · Completed · Phase 2
Theriva Biologics SL
2023–2025
Tempus CRC Surveillance Study: A ctDNA Biomarker Profiling Study of Patients With CRC Using NGS Assays
Site PI · Recruiting
Tempus AI
2022–2029